Skip to main
CVRX

CVRx (CVRX) Stock Forecast & Price Target

CVRx (CVRX) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CVRx is expected to experience strong growth in the US market as it continues to market and sell Barostim therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). The company's improved sales strategy and focus on high-potential accounts are expected to drive further growth. The success of their product, BAROSTIM NEO, in combination with continued physician and patient marketing efforts, adequate reimbursement, and favorable clinical data, will also contribute to their growth. However, there are risks associated with limited long-term clinical data, reliance on third-party suppliers, and potential dilution. Management remains confident in their 2026 guidance and reiterated their projected revenue and margins for the year.

Bears say

CVRx is currently facing several challenges that may hinder its success in the future. These include its high reliance on the U.S. market for revenue, as well as its concentration on a single product, the BAROSTIM NEO, which has limited long-term clinical data on safety and efficacy. Additionally, CVRx's success is heavily dependent on its ability to demonstrate the benefits of BAROSTIM therapy to physicians and secure adequate reimbursement from government health authorities and insurers. The company also faces the risk of dilution due to its expectation of losses and potential need for future financing.

CVRx (CVRX) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVRx (CVRX) Forecast

Analysts have given CVRx (CVRX) a Buy based on their latest research and market trends.

According to 2 analysts, CVRx (CVRX) has a Buy consensus rating as of Jun 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVRx (CVRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.